Overexpression of ABCB1 has been shown to be associated with drug resistance in a number of different tumour types [44], including ceritinib resistance in non-small cell lung cancer [45], and with poor clinical outcomes, such as response to chemotherapy in breast cancer [46]. Here, ABCB1 is linked to neoplasm.